Personalized Stem Cells is committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.
Personalized Stem Cells (PSC) recently received FDA approval to treat COVID-19 patients with stem cells in an upcoming clinical trial.
The COVID-19 pandemic has changed our way of life these past few months. The Personalized Stem Cells team has been working hard to continue manufacturing stem cell doses for current and potential clinical trial participants.
Personalized Stem Cells, Inc. (PSC) is raising the standard of Stem Cell therapy. We are committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and...
Personalized Stem Cells’ (PSC) clinical trial may provide data to help determine if treatment with stem cells may help patients avoid knee replacement surgery.
PSC Medical Director, Dr. Christopher Rogers, recently spoke at the annual TOBI conference on mesenchymal stem cells for the treatment of COVID-19.
PSC stores adipose (fat) derived stem cells from clinical trial participants in our FDA-inspected facility. Stored stem cells can potentially be used to treat future approved conditions.
Stem cell therapies have many potential uses. If seeking treatment with stem cells, it is advisable to confirm FDA oversight of the treatment or clinical trial.
Dr. Christopher Rogers is the Medical Director of Personalized Stem Cells, Inc. An expert in Regenerative Medicine with more than twenty-five years of clinical experience, Dr. Rogers is one of the investigators in PSC’s first FDA approved clinical trial.
On April 27, 2020 PSC CEO, Dr. Bob Harman and PSC Medical Director, Dr. Christopher Rogers, were interviewed by San Diego CBS affiliate, KFMB TV, regarding stem cell therapy for COVID-19.